DMII — Drugs Made In America Acquisition II Balance Sheet
0.000.00%
Last trade - 00:00- $640.82m
- $640.92m
Annual balance sheet for Drugs Made In America Acquisition II, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2024 December 31st | 2025 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Cash | ||
| Cash and Short Term Investments | 0.017 | 0 |
| Prepaid Expenses | ||
| Total Current Assets | 0.06 | 0.026 |
| Other Long Term Assets | ||
| Total Assets | 0.138 | 505 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Total Current Liabilities | 0.255 | 0.301 |
| Total Long Term Debt | ||
| Total Debt | ||
| Total Other Liabilities | ||
| Total Liabilities | 0.255 | 17.8 |
| Common Stock | ||
| Additional Paid In Capital | ||
| Retained Earnings (Accumulated Deficit) | ||
| Total Equity | -0.117 | 487 |
| Total Liabilities & Shareholders' Equity | 0.138 | 505 |
| Total Common Shares Outstanding |